ReviewTherapeutic advances in medical oncology2022
Predicting response to neoadjuvant chemoradiotherapy in rectal cancer: from biomarkers to tumor models.
Review in Therapeutic advances in medical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Machine learning in predicting pathological complete response to neoadjuvant chemoradiotherapy in rectal cancer using MRI: a systematic review and meta-analysis.The British journal of radiology · 2024Pooled it
- Profiling neoadjuvant therapy response in rectal cancer using meta-analysis of publicly available transcriptomic RNA-seq datasets.Molecular oncology · 2026Article
- A simple MRI/PET-derived index predicts relapse-free survival after neoadjuvant chemoradiotherapy in locally advanced rectal cancer.Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland · 2026Article
- NF-κB-active tumors with matrix CAFs and suppressive immunity as key resistance mechanisms to chemoradiation in rectal cancer.Experimental & molecular medicine · 2026Article
- Patient-Derived Functional Models for Prediction of Radiotherapy Response in Rectal Cancer: A Systematic Review and Exploratory HSROC Meta-Analysis.Life (Basel, Switzerland) · 2026Review
- Identification of an Immune Cell Gene Signature for Predicting Response and Prognosis in Rectal Cancer Patients Undergoing Neoadjuvant Chemoradiotherapy.Cancer medicine · 2026Article
- Targeting Ferroptosis to Overcome Radioresistance and Enhance Immunotherapy in Colorectal Cancer.Cells · 2026Review
- Impact of Body Weight Loss During Preoperative Chemoradiotherapy on Prognosis of Patients With Lower Rectal Cancer.Annals of gastroenterological surgery · 2026Article
- Variant-to-Biomarker Integration and Mechanistic Validation Identify CES1 as a Copy Number-Linked Predictor of Radiotherapy Response in Rectal Cancer.Human mutation · 2026Article
- The role of serum adipokines in predicting response to neoadjuvant therapy in patients with locally advanced rectal cancer.Revista da Associacao Medica Brasileira (1992) · 2026Article
- Response Prediction of Chemoradiotherapy for Rectal Cancer Using Rapid Semi-Automated Flow Cytometry.Cancers · 2025Article
- The long antisense non-coding RNA HOXA transcript at the distal tip (LncRNA HOTTIP) in health and disease: a comprehensive review and in silico analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Predicting neoadjuvant chemoradiotherapy response in rectal cancer: Insights from biomarkers to clinical practice.World journal of gastrointestinal surgery · 2025Review
- Controversies and Perspectives in the Current Management of Patients with Locally Advanced Rectal Cancer-A Systematic Review.Life (Basel, Switzerland) · 2025Review
- Combination of intravoxel incoherent motion histogram parameters and clinical characteristics for predicting response to neoadjuvant chemoradiation in patients with locally advanced rectal cancer.Abdominal radiology (New York) · 2025Article
- Comparative Outcomes of Neo-Adjuvant Chemo-Radiotherapy in Stage II and III Mucinous versus Non-Mucinous Rectal Adenocarcinoma: A Retrospective Study.Cancer management and research · 2025Article
- Development and validation of a prognostic signature of breast cancer based on drug absorption, distribution, metabolism and excretion (ADME)-related genes.Scientific reports · 2024Article
- Could Flow Cytometry Provide New Prognostic Markers in Colorectal Cancer?Journal of clinical medicine · 2024Article
- Current Applications and Future Directions of Circulating Tumor Cells in Colorectal Cancer Recurrence.Cancers · 2024Review
- Effectiveness and safety of neoadjuvant apatinib in combination with capecitabine and oxaliplatin for the therapy of locally advanced colorectal cancer: A retrospective study.Oncology letters · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a major contributor to cancer-associated morbidity worldwide and over one-third of CRC is located in the rectum. Neoadjuvant chemoradiotherapy (nCRT) followed by surgical resection is commonly applied to treat locally advanced rectal cancer (LARC). In this review, we summarize current and novel concepts of neoadjuvant therapy for LARC such as total neoadjuvant therapy and describe how these developments impact treatment response. Moreover, as response to nCRT is highly divergent in rectal cancers, we discuss the role of potential predictive biomarkers. We review recent advances in biomarker discovery, from a clinical as well as a histopathological and molecular perspective. Furthermore, the role of emerging predictive biomarkers derived from the tumor environment such as immune cell composition and gut microbiome is presented. Finally, we describe how different tumor models such as patient-derived cancer organoids are used to identify novel predictive biomarkers for chemoradiotherapy (CRT) in rectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.